

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-46. Canceled.

47. (Presently Amended) A pharmaceutical composition comprising an antibody having human IgG1 isotype that specifically binds to an epitope within residues 1-7 of A β and a pharmaceutical carrier.

48-68. Canceled

69. (Presently Amended) [The]A pharmaceutical composition [of claim 47, wherein the] comprising an antibody that specifically binds to an epitope within residues 1-4 of A β and a pharmaceutical carrier.

70. (Presently Amended) [The]A pharmaceutical composition [of claim 47, wherein the] comprising an antibody that specifically binds to an epitope within residues 1-3 of A β and a pharmaceutical carrier.

71. (Previously Presented) The pharmaceutical composition of claim 47, wherein the antibody specifically binds to an epitope within residues 3-7 of A β .

72. (New) A pharmaceutical composition comprising a chimeric, humanized or human antibody that specifically binds to an epitope within residues 1-7 of A β and a pharmaceutical carrier.

73. (New) The pharmaceutical composition of claim 47, which is a sustained release composition.

74. (New) The pharmaceutical composition of claim 72, which is a sustained release composition.

Art Unit: 1647

Claims 1-46 (Cancelled)

¹
Claim ~~47~~ (Currently Amended) A pharmaceutical composition comprising an antibody having human IgG1 isotype that specifically binds to an epitope within residues 1-7 of A β and a pharmaceutical carrier, wherein the isotype of said antibody is human IgG1.

Claims 48-68 (Cancelled)

²
Claim ~~69~~ (Currently Amended) A The pharmaceutical composition according claim ~~47~~, wherein said antibody comprising an antibody that specifically binds to an epitope within residues 1-4 of A β and a pharmaceutical carrier.

³
Claim ~~70~~ (Currently Amended) A The pharmaceutical composition according claim ~~47~~, wherein said antibody comprising an antibody that specifically binds to an epitope within residues 1-3 of A β and a pharmaceutical carrier.

⁴
Claim ~~71~~ (Previously Amended) The pharmaceutical composition of claim ~~47~~, wherein the antibody specifically binds to an epitope within residues 3-7 of A β .

⁶
Claim ~~72~~ (Currently Amended) A pharmaceutical composition comprising a chimeric, or humanized ~~or human~~ antibody that specifically binds to an epitope within residues 1-7 of A β and a pharmaceutical carrier.

Art Unit: 1647

cont.

⁶
Claim ~~73~~ (Previously Added) The pharmaceutical composition of claim ¹~~47~~, which is a sustained release composition.

^X
Claim ~~74~~ (Previously Added) The pharmaceutical composition of claim ⁶~~72~~, which is a sustained release composition.

5. Authorization for this examiner's amendment was given in a telephone interview with Rosemaire Celli (Reg. No. 42,397) on 14 November 2003.

In the Title:

N-TERMINAL AMYLOID-BETA ANTIBODIES

REASONS FOR ALLOWANCE

6. The following is an examiner's statement of reasons for allowance:
7. The references cited herein were found by the Examiner during the art searches while preparing the instant Application for allowance. None of the references teach or fairly suggest a human antibody that is specific for an epitope within residues 1-12 (and subsets within) of A β .
8. Claims 69 and 70 were amended to be dependent from claim 47 to correct an error made without deceptive intent made by Applicant in the Amendment filed 3 September 2003.